Application of lnc-znf100-5 functional expression inhibitor in preparation of medicine for treating breast cancer

A functional, inhibitory technology for biomedical applications

Active Publication Date: 2022-06-03
NANTONG UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, lncRNAs are still in their infancy, and only a few cancer-related lncRNAs have been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lnc-znf100-5 functional expression inhibitor in preparation of medicine for treating breast cancer
  • Application of lnc-znf100-5 functional expression inhibitor in preparation of medicine for treating breast cancer
  • Application of lnc-znf100-5 functional expression inhibitor in preparation of medicine for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The present invention designs an experiment aimed at the expression of lnc-ZNF100-5 in breast cancer cells, aiming to find out whether lnc-ZNF100-5 is highly expressed in breast cancer cells. The expression of lnc-ZNF100-5 in breast cancer cells MCF-7 and MDA-MB-231 was detected by fluorescent quantitative PCR. The specific experimental steps are as follows:

[0020] Fluorescence quantitative PCR experiment steps:

[0021] 1. Total RNA was collected from cells and tissue samples using Trizol reagent (Invitrogen, Carlsbad, USA). Aspirate the culture medium of breast cancer cells MCF-7 and MDA-MB-231 in the 6-well plate, add 1ml Trizol to each well to cover the cells, then pipette 3 times with a pipette or pipette, the cells should be completely lysed, Then transfer to a centrifuge tube. Add 0.2 mL of chloroform (0.2 mL of chloroform to 1 mL of Trizol) into the centrifuge tube containing the lysate, shake and mix well on the shaker for 20 seconds, and place at room ...

Embodiment 2

[0028]According to literature reports, in addition to shRNA lentivirus, there are many technical means that can also achieve the functional expression of lnc-ZNF100-5, or inhibit the functional expression of substances related to the downstream of lnc-ZNF100-5, thereby inhibiting The function of lnc-ZNF100-5 for the prevention or treatment of breast cancer. These techniques include but are not limited to other RNAi techniques (inhibiting the functional expression of lnc-ZNF100-5 by other siRNAs), Clustered Regularly Interspaced Short Palindromic Repeats (CRRSPR) technique (using a sequence-specific guide RNA molecule (sequence- specific guide RNA, sgRNA) to guide the endonuclease to the target site, thereby completing genome editing, especially represented by CRISPR / Cas9 technology), zinc finger nuclease (ZFN) technology (by processing and transforming the zinc finger DNA of ZFN Binding domains, targeting at different DNA sequences), transcription activator-like effector nucle...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of an lnc-ZNF100-5 functional expression inhibitor in the preparation of a drug for treating breast cancer, and belongs to the technical field of biomedicine. The lnc-ZNF100-5 functional expression inhibitor is RNAi, shRNA lentivirus, sgRNA, ZFN, TALEN element or homologous recombination vector. In the present invention, the expression of lnc-ZNF100-5 in breast cancer cells is significantly increased, which can be used for the detection of breast cancer, and an in vitro lnc-ZNF100-5 knockout breast cancer cell model and an in vivo lnc-ZNF100-5 knockout breast cancer cell model are established. A series of experimental studies on cancer orthotopic xenograft models have demonstrated that lnc‑ZNF100‑5 can significantly inhibit the proliferation of breast cancer cells and significantly promote the apoptosis of breast cancer cells. Knocking out lnc‑ZNF100‑5 can be used for prevention or treatment Breast cancer, so that lnc-ZNF100-5 functional expression inhibitor can be prepared to treat breast cancer.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and specifically relates to the application of lnc-ZNF100-5 functional expression inhibitors in the preparation of drugs for treating breast cancer. Background technique [0002] The World Health Organization's International Agency for Research on Cancer (IARC) released the latest global cancer burden data for 2020: 19.29 million new cancer cases worldwide in 2020. One of the most obvious changes is the rapid increase in the number of new cases of breast cancer reaching 2.26 million, officially replacing lung cancer (2.2 million) as the world's largest cancer for the first time, accounting for 11.7% of all new cancer patients. Breast cancer is the first malignant tumor that seriously threatens the health of women all over the world. Among new breast cancer cases each year, about 3%-10% of women have distant metastases at the time of diagnosis. Among early stage patients, 30% can develop adv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886A61K45/00A61P35/00A61P15/14
CPCC12Q1/6886A61K45/00A61P35/00A61P15/14C12Q2600/158C12Q2600/178C12Q2600/136
Inventor 王国华孙祥琳周佳敏张馨予吴昊杨欢姜正林
Owner NANTONG UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap